Pharmacogenetics and Genomics

Scope & Guideline

Transforming pharmacotherapy with innovative research.

Introduction

Delve into the academic richness of Pharmacogenetics and Genomics with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN1744-6872
PublisherLIPPINCOTT WILLIAMS & WILKINS
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 2005 to 2024
AbbreviationPHARMACOGENET GENOM / Pharmacogenet. Genomics
Frequency9 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressTWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103

Aims and Scopes

The journal "Pharmacogenetics and Genomics" focuses on the intersection of pharmacogenetics and clinical practice, emphasizing how genetic variations influence drug responses and efficacy. Its core aim is to advance personalized medicine through the integration of genetic testing in therapeutic decisions.
  1. Pharmacogenetic Variability and Drug Response:
    The journal extensively covers research that elucidates how genetic polymorphisms affect individual responses to medications, including efficacy and toxicity, thereby contributing to personalized treatment strategies.
  2. Clinical Implementation of Pharmacogenetics:
    A significant focus is on the practical application of pharmacogenetic testing in clinical settings, evaluating how such implementations can enhance patient care and treatment outcomes.
  3. Genetic Mechanisms and Pathways:
    Research published in the journal often explores the biological mechanisms underlying pharmacogenetic variability, including gene-drug interactions and metabolic pathways.
  4. Population-Specific Pharmacogenetics:
    The journal highlights studies that investigate pharmacogenetic variations across different populations, addressing disparities in drug response and treatment effectiveness.
  5. Emerging Technologies in Pharmacogenomics:
    The integration of new technologies such as CRISPR, genome-wide association studies, and high-throughput sequencing is a consistent theme, driving advancements in pharmacogenetic research.
The journal has witnessed a rise in certain themes that reflect current trends and emerging areas of interest within pharmacogenetics and genomics. These trends signify the evolving landscape of personalized medicine.
  1. Integration of Pharmacogenomics in Clinical Guidelines:
    There is an increasing focus on how pharmacogenomic data can be incorporated into clinical guidelines, enhancing decision-making in drug therapy and improving patient outcomes.
  2. Research on Polygenic Risk Scores:
    Studies exploring polygenic risk scores to predict drug response and adverse effects are gaining traction, highlighting the complexity of genetic influences on pharmacotherapy.
  3. Pharmacogenetics in Oncology:
    An emerging theme is the application of pharmacogenetics in oncology, where genetic variations are linked to responses to chemotherapy and targeted therapies, driving personalized cancer treatment.
  4. Real-World Evidence and Implementation Studies:
    There is a significant increase in research utilizing real-world data to assess the impact of pharmacogenetic testing on treatment outcomes, reflecting a shift towards practical applications in healthcare.
  5. Patient-Centric Pharmacogenetic Research:
    New studies are emphasizing patient perspectives and experiences regarding pharmacogenetic testing, indicating a trend towards more holistic approaches in pharmacogenomics.

Declining or Waning

While the journal continues to thrive in various areas of pharmacogenetics, some themes have shown a decline in focus over recent years, reflecting shifts in research priorities and emerging scientific interests.
  1. Traditional Drug Interaction Studies:
    Research centered solely on traditional drug-drug interactions, without considering genetic factors, appears less frequently, as the field moves towards a more integrated approach that includes genetic profiling.
  2. Single Gene Studies:
    There is a noticeable reduction in studies focusing exclusively on single gene polymorphisms, as the field increasingly embraces comprehensive genomic approaches and polygenic risk scores.
  3. General Population Studies:
    Investigations that do not account for specific demographic or ethnic variations are becoming less common, reflecting a trend towards more nuanced research that recognizes the importance of population genetics.
  4. Basic Science without Clinical Application:
    Research that remains purely within the domain of basic science, without a clear path to clinical application or relevance, is less frequently published, indicating a shift towards translational research.

Similar Journals

Precision and Future Medicine

Pioneering research for a personalized medical landscape.
Publisher: SUNGKYUNKWAN UNIV SCH MEDICINEISSN: 2508-7940Frequency: 4 issues/year

Precision and Future Medicine is an esteemed academic journal published by Sungkyunkwan University School of Medicine, dedicated to advancing the fields of precision medicine and healthcare innovation. Established as an Open Access journal in 2017, it aims to disseminate cutting-edge research and insights that bridge the gap between basic and clinical sciences. With a focus on personalized medicine, genomics, and advanced therapeutic strategies, the journal serves as a vital resource for researchers, clinicians, and policy makers. Set in the dynamic environment of South Korea, Precision and Future Medicine provides a platform for the exchange of ideas that are shaping the future of medical science, thus contributing significantly to the global dialogue on health and wellness. As it continues to grow, the journal is committed to ensuring that high-quality research remains accessible to all, fostering a spirit of collaboration and innovation within the scientific community.

Pharmacogenomics & Personalized Medicine

Pioneering advancements in pharmacogenomics for a healthier tomorrow.
Publisher: DOVE MEDICAL PRESS LTDISSN: Frequency: 1 issue/year

Pharmacogenomics & Personalized Medicine is a premier open-access journal published by DOVE MEDICAL PRESS LTD, focusing on the vital intersection of pharmacogenomics, pharmacology, and personalized approaches to medicine. Launched in 2008 and based in New Zealand, this journal plays an essential role in disseminating cutting-edge research that aims to enhance therapeutic efficacy through individualized treatment strategies. With its Q3 ranking in both Molecular Medicine and Pharmacology as of 2023, Pharmacogenomics & Personalized Medicine is gaining momentum in the scientific community, providing a platform for researchers to explore significant findings and their implications for patient care. The journal's commitment to open access ensures that valuable information is readily available to a global audience, promoting collaboration and innovation across various fields of health science. We invite researchers, professionals, and students to contribute and explore groundbreaking studies that pave the way for advancements in personalized healthcare.

BMC Medical Genomics

Innovating Healthcare Solutions Through Genomic Research
Publisher: BMCISSN: Frequency: 1 issue/year

BMC Medical Genomics is a prominent peer-reviewed open-access journal published by BMC, specializing in the integration of genomics within the medical field. Since its inception in 2008, this journal has positioned itself at the forefront of genomic research, contributing to significant advancements in understanding the genetic underpinnings of diseases. With an impressive impact factor reflective of its rigorous scholarship, BMC Medical Genomics holds a prestigious Q2 ranking in the field of Genetics and a Q3 ranking in Clinical Genetics, showcasing its relevance and influence in shaping contemporary research paradigms. The journal is recognized in various databases, including Scopus, where it ranks 58th in Clinical Genetics, emphasizing its importance within the medical community. By facilitating open access to its comprehensive articles, BMC Medical Genomics aims to foster collaboration among researchers, healthcare professionals, and students, thereby enhancing the collective understanding of genomics in medicine. Its commitment to delivering high-quality research makes it an essential resource for those immersed in this dynamic and rapidly evolving field.

NATURE GENETICS

Advancing Knowledge in Genetic Mechanisms
Publisher: NATURE PORTFOLIOISSN: 1061-4036Frequency: 12 issues/year

Nature Genetics is a premier journal in the field of genetics published by NATURE PORTFOLIO, renowned for its impactful research and significant contributions to the understanding of genetic mechanisms and their implications for human health. Since its establishment in 1992, the journal has continually maintained a strong reputation, evidenced by its impressive Q1 ranking in the Genetics category and a commendable Scopus ranking of #4 out of 347 in Genetics, placing it in the 98th percentile. Although it does not currently offer Open Access options, Nature Genetics remains a critical resource for researchers and practitioners, providing cutting-edge studies and papers that drive advancements in both fundamental and applied genetic research. With a global readership and contributions from leading scientists around the world, this journal is a vital platform for disseminating innovative findings and fostering discussions at the frontier of genetics.

Cancer Genetics

Innovating Cancer Treatment with Genetic Discoveries
Publisher: ELSEVIER SCIENCE INCISSN: 2210-7762Frequency: 6 issues/year

Cancer Genetics is an esteemed peer-reviewed journal dedicated to advancing the field of cancer research through the lens of genetics. Published by Elsevier Science Inc and available in both print (ISSN: 2210-7762) and online (E-ISSN: 2210-7770), this journal aims to provide a platform for the dissemination of high-quality studies that unravel the genetic underpinnings of cancer. Since its inception in 2011, Cancer Genetics has become a significant resource for researchers, professionals, and students with a shared interest in understanding the intricate relationship between genetics and oncogenesis. With an impact factor that reflects its influence, the journal has maintained a Q3 ranking in Cancer Research, Genetics, and Molecular Biology as of 2023, indicating its growing importance in these fields. Additionally, the journal offers open access options to ensure that crucial findings are easily accessible to the global research community. By bridging the gap between genetics and cancer studies, Cancer Genetics plays a pivotal role in fostering innovation and collaboration among scientists and clinicians striving to improve cancer diagnosis and treatment.

INTERNATIONAL JOURNAL OF ONCOLOGY

Advancing cancer research for a healthier tomorrow.
Publisher: SPANDIDOS PUBL LTDISSN: 1019-6439Frequency: 12 issues/year

INTERNATIONAL JOURNAL OF ONCOLOGY is a leading academic publication dedicated to advancing the field of cancer research and treatment. Published by SPANDIDOS PUBL LTD in Greece, this journal, with ISSN 1019-6439 and E-ISSN 1791-2423, has established itself as a reputable source of peer-reviewed articles since its inception in 1993. With an impressive Q2 ranking in both Cancer Research and Oncology categories, as well as high Scopus ranks reflecting its significant contribution to the fields of Medicine and Biochemistry, the journal offers a platform for researchers, clinicians, and students alike to disseminate their findings and engage in dialogue surrounding innovative practices and breakthroughs. Although the journal follows a traditional subscription model, it continues to attract a diverse readership interested in the latest developments in oncological research, providing essential insights into cancer biology, therapeutics, and patient care. With a commitment to excellence, the INTERNATIONAL JOURNAL OF ONCOLOGY plays a vital role in shaping the future of oncology research and is a must-read for anyone passionate about advancing cancer treatment and prevention.

Frontiers in Genetics

Pioneering Interdisciplinary Insights in Genetics
Publisher: FRONTIERS MEDIA SAISSN: Frequency: 1 issue/year

Frontiers in Genetics is a premier academic journal dedicated to advancing the field of genetics through high-quality, peer-reviewed research. Published by FRONTIERS MEDIA SA in Switzerland since 2010, this Open Access journal provides a platform for researchers and practitioners to disseminate innovative findings across various subfields, including clinical genetics and molecular medicine. With a notable emphasis on interdisciplinary approaches, the journal holds a strong position in the academic landscape, achieving Q2 rankings in key categories such as Genetics and Molecular Medicine in 2023. Not only does Frontiers in Genetics contribute to the scholarly dialogue by publishing impactful studies, but it also promotes accessibility to vital research, ensuring that knowledge is available to a global audience. This journal is a vital resource for researchers, professionals, and students looking to stay at the forefront of genetic discoveries and their applications, reflective of its engagement with contemporary challenges in genetics and healthcare.

Cardiogenetics

Advancing cardiovascular health through genetic insights.
Publisher: MDPIISSN: 2035-8253Frequency: 4 issues/year

Cardiogenetics, published by MDPI, is a leading open-access journal dedicated to advancing the field of genetics as it pertains to cardiovascular health and diseases. Since its launch in 2011, this journal has been at the forefront of disseminating high-quality research that explores the genetic underpinnings of cardiovascular conditions, offering a platform for innovative studies, reviews, and case reports. With an ISSN of 2035-8253 and an E-ISSN of 2035-8148, Cardiogenetics aims to bridge the gap between genetic research and clinical application, helping researchers, healthcare professionals, and students stay abreast of the latest advancements and findings. The journal’s commitment to open access ensures that its valuable content is available to a global audience, fostering greater collaboration and knowledge sharing in the cardiovascular genetics community. By contributing to this dynamic field, Cardiogenetics plays a crucial role in improving patient outcomes and paving the way for personalized medicine in cardiology.

CLINICAL PHARMACOKINETICS

Elevating Pharmacological Knowledge Since 1976
Publisher: ADIS INT LTDISSN: 0312-5963Frequency: 12 issues/year

CLINICAL PHARMACOKINETICS, published by ADIS INT LTD, is a premier journal dedicated to the field of pharmacology, with a distinguished reputation since its inception in 1976. With an impressive impact factor and categorized in the Q1 quartile for both general pharmacology and medical pharmacology, this journal ranks #29 out of 272 and #53 out of 313 in its respective categories in Scopus, highlighting its high academic influence and the quality of research it publishes. CLINICAL PHARMACOKINETICS serves as a vital resource for researchers, professionals, and students interested in the latest advancements in drug metabolism, therapeutic efficacy, and clinical applications of pharmacokinetic studies. As it continues to evolve through 2024 and beyond, the journal remains committed to fostering a deeper understanding of pharmacotherapy and its implications in clinical practice. While it does not currently offer open access, the journal ensures that cutting-edge research is accessible through various academic platforms.

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Elevating standards in clinical pharmacy and patient care.
Publisher: WILEY-HINDAWIISSN: 0269-4727Frequency: 1 issue/year

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, an esteemed publication in the field of pharmacology, is published by Wiley-Hindawi and has been at the forefront of clinical research since its inception in 1976. Operating primarily from the United Kingdom, this journal features a diverse array of articles that encompass both fundamental and practical aspects of clinical pharmacy, thereby supporting the advancement of therapeutic practices. With an ISSN of 0269-4727 and an E-ISSN of 1365-2710, it is indexed in key databases and holds respectable ranks within its categories; achieving Q3 in Pharmacology and Q2 in Medical Pharmacology in the latest quartile rankings. Its Scopus ranking reflects both its quality and relevance, being positioned in the 55th percentile for medical pharmacology and the 45th for pharmacology, toxicology, and pharmaceutics. Although it does not currently operate under an Open Access model, the journal's extensive readership and rigorous peer-review process ensure that the latest research reaches practitioners and academics alike. With a commitment to bridging the gap between pharmacological science and clinical practice, the JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS remains a critical resource for professionals striving to enhance patient outcomes through informed medication management.